MSD presented the 5-year data on the efficacy and safety of the PD-1 (Programmed Cell Death 1 Protein) inhibitor pembrolizumab (KEYTRUDA®) as monotherapy in patients with advanced disease non-small cell lung cancer (NSCLC) known from the first KEYNOTE study (KEYNOTE-001, phase Ib). In this study, treatment with pembrolizumab resulted in 5-year overall survival (OS) of 23.2% in previously treated patients (n = 101) and 15.5% in previously treated patients (n = 449). It should be emphasized that the 5-year OS in untreated patients with high PD-L1 expression (Tumor Proportion Score [TPS] ≥ 50%) was 29.6% (n = 27) and 25.0% (n = 138) in the previously treated patients. These results represent the longest follow-up on pembrolizumab in lung cancer and were presented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting. Dr. Edward B. Garon, MD, MS, of the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, said the results of the KEYNOTE-001 study were encouraging.
Source: MSD Sharp & Dohme GmbH, www .msd-immunonkologie.de